B1401
缓激肽片段 1-5
≥97% (HPLC)
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C27H40N8O6
化学文摘社编号:
分子量:
572.66
NACRES:
NA.32
PubChem Substance ID:
UNSPSC Code:
12352200
MDL number:
Form:
powder
Assay:
≥97% (HPLC)
产品名称
缓激肽片段 1-5, ≥97% (HPLC)
InChI
1S/C27H40N8O6/c28-18(9-4-12-31-27(29)30)24(38)35-14-6-11-21(35)25(39)34-13-5-10-20(34)23(37)32-16-22(36)33-19(26(40)41)15-17-7-2-1-3-8-17/h1-3,7-8,18-21H,4-6,9-16,28H2,(H,32,37)(H,33,36)(H,40,41)(H4,29,30,31)
SMILES string
NC(CCCNC(N)=N)C(=O)N1CCCC1C(=O)N2CCCC2C(=O)NCC(=O)NC(Cc3ccccc3)C(O)=O
InChI key
USSUMSBPLJWFSZ-UHFFFAOYSA-N
assay
≥97% (HPLC)
form
powder
UniProt accession no.
storage temp.
−20°C
Quality Level
Gene Information
human ... KNG1 (includes EG:3827)
Biochem/physiol Actions
缓激肽(BK)片段(1-5)(RPPGF)是最稳定的天然代谢产物之一。可作为体内缓激肽产生的标志物。其生物活性依赖于C末端的一个完整的精氨酸(Arg)残基。BK 1-5是抑制α-凝血酶诱导的血小板聚集和分泌及钙离子动员的必需肽。还可抑制α-凝血酶在精氨酸和丝氨酸之间的位点切割凝血酶受体肽NATLDPRSFLLR。BK 1-5的这种抗凝血酶活性可能与激肽的心脏保护作用有关。
Packaging
无底玻璃瓶。内含物装在锥底内插管中。
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves, type N95 (US)
法规信息
常规特殊物品
此项目有
T A Morinelli et al.
The Journal of pharmacology and experimental therapeutics, 296(1), 71-76 (2000-12-21)
Extensive research has provided few therapeutic agents for the treatment of septicemia. Bradykinin, an endogenous vasodepressor hormone, is a key mediator in the hypotension seen with septicemia. The present investigation shows that a stable metabolic fragment of bradykinin, arginine-proline-proline-glycine-phenylalanine (RPPGF)
L J Murphey et al.
Circulation, 102(8), 829-832 (2000-08-23)
Bradykinin is a cardioprotective peptide metabolized by the angiotensin-converting enzyme (ACE). An insertion/deletion (I/D) polymorphism in the ACE gene determines plasma ACE levels. The D allele is associated with cardiovascular disease, which may relate to enhanced angiotensin II production or
Marvin T Nieman et al.
Thrombosis and haemostasis, 104(5), 1044-1048 (2010-10-05)
Thrombin stimulates proliferation, invasion and metastasis by cleaving protease-activated receptor 1 (PAR1) on human prostate cancer cells. Current direct thrombin inhibitors pose risks for bleeding in the cancer patients. We have developed an oral reversible direct thrombin inhibitor called FM19.
Marvin T Nieman et al.
The Journal of pharmacology and experimental therapeutics, 311(2), 492-501 (2004-06-24)
Thrombin and protease-activated receptor 1 (PAR1) activation antagonists were prepared based upon the peptide RPPGF, the angiotensin-converting enzyme breakdown product of bradykinin. A library of 72 peptides consisting of d and/or synthetic amino acids was designed with various substitutions in
Cho Yeow Koh et al.
Thrombosis and haemostasis, 102(3), 437-453 (2009-09-01)
To obtain blood meals, haematophagous animals are armed with potent pharmacological molecules to overcome several of their hosts' response systems. Among them, a large number of exogenous anticoagulants which target the haemostatic system have been identified and characterised. Studies on
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持